Clinical Trial

Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer

Recruiting Phase 2/3
View on ClinicalTrials.gov →
Record status
This record was last updated May 1, 2024 (before its estimated March 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
To evaluate the clinical efficacy and safety of Tislelizumab combined with apatinib mesylate, oxaliplatin plus S1 Vs oxaliplatin plus S1.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-01-17; most recent amendment 2024-04-30.
Status change: Not Yet Recruiting → Recruiting 2023-06-14
Trial Details
NCT Number NCT05699655
Lead Sponsor Fujian Cancer Hospital
Conditions Immunotherapy Gastrict Cancer
Enrollment 130 participants
Start Date 2023-05-10
Primary Completion 2025-03-01 (estimated)
Study Completion 2027-04-01 (estimated)
Updated on ClinicalTrials.gov 2024-05-01